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Abstract
Because of the continuous decrease of sequencing prices the GA4GH has estimated 
that by 2023 over 80% of sequencing will be done in a clinical environment. In addition, 
more than two decades of generalized digitalization of health systems is generating an 
immense repository of clinical big data. Moreover, in coming years wearable devices will 
be mainstream for monitoring chronic patients and the elder, producing an enormous 
amount of health and life style data. On the other hand, the field of artificial intelligence 
has experienced an enormous activity in the last years, releasing a plethora of new 
methods or new versions of classical ones, able to find patterns in large datasets, to 
produce classifications using highly dimensionality data or to derive predictors of unpre-
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cedented precision. All this together offer an unprecedented opportunity to analyze this 
wealth of real world data (RWD) to generate new biomedical knowledge with an enor-
mous translational potential. However, several obstacles preclude the direct exploitation 
of this data. Firstly, most of this data are highly sensitive and are consequently affected 
by data protection laws and regulations, which impose severe regulations to its use, 
especially outside of the health system. Moreover, much of this data are contained in 
unconnected silos in a non-homogeneous format. Here we will comment some initiati-
ves to integrate genomic and clinical data within the Andalusian Public Health System 
and to make a systematic exploitation to generate new biomedical knowledge using 
artificial intelligence.
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